Meglumine antimoniate adverse reactions

Revision as of 03:42, 7 January 2014 by Gerald Chi (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Meglumine Antimoniate
GLUCANTIM® WHO Prescribing Information
Description
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Dosage and Administration
How Supplied

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Adverse effects

Electrocardiographic changes are dose-dependent and usually reversible; typically, T-wave inversion and prolongation of the Q-T interval precede serious dysrhythmias.

Hepatic and renal function may be impaired.

Headache, malaise, dyspnoea, skin rashes, facial oedema and abdominal pain are also occasionally associated with treatment.[1]

References

  1. "WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate".

Adapted from the FDA Package Insert.